Skip to content

Cerus CERS Total debt

Total debt at other companies

Haemonetics logo
HaemoneticsHAE
$1.27B-0.7%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$987.3M-28.4%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$9.78M-13.9%
QuidelOrtho Corporation logo
QuidelOrtho CorporationQDEL
$3.1B+0.3%
ADMA Biologics logo
ADMA BiologicsADMA
$204.41M+2,055%
Paysign logo
PaysignPAYS
$12.06M-4.6%

Other financials

Income statement

See full
Revenue$53.7M+24.1%
Operating income-$354.0K+94.0%
Net income-$1.6M+78.7%
EPS (diluted)-$0.01+75.0%

Balance sheet

See full
Cash & equivalents$27.9M+43.0%
Total equity$67.6M+21.7%
Total assets$222.9M+7.8%

Cash flow

See full
Operating cash flow-$3.0M-261%
CapEx$233.0K+108%
Free cash flow-$3.3M-243%

Valuation

See full
Market cap$573.06M+124%
Enterprise value$590.17M+86.7%
P/S2.9×-1.0×

Profitability

See full
Gross margin64%
Operating margin-6.2%-2.1pp
Net margin-9.8%-2.8pp
FCF margin3.5%+1.9pp

Returns & leverage

See full
Return on equity-15.5%-5.6pp
Debt / equity0.7×-0.8×
Current ratio1.6×-0.7×

Where this comes from

Calculated from Cerus’s reported figures.

Plus components not separately reported this period.

The official record: Cerus’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cerus's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cerus's total debt?
Cerus (CERS) reported total debt of $44.96M in Q1 2026.
How has Cerus's total debt changed year-over-year?
Cerus's total debt decreased by 43.3% year-over-year, from $79.35M to $44.96M.
What is the long-term trend for Cerus's total debt?
Over 5 years (2020 to 2025), Cerus's total debt has grown at a -1.7% compound annual growth rate (CAGR), from $58.38M to $53.6M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.